Horenstein, Richard B <br/><br/>
Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.  [electronic resource] 

 -  Journal of clinical pharmacology  Aug 2014 
 - 865-73 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1552-4604 
<br/><br/><label>Standard No.: </label>10.1002/jcph.293  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Amish--genetics<br/>Area Under Curve<br/>Clopidogrel<br/>Cross-Over Studies<br/>Cytochrome P-450 CYP2C19--metabolism<br/>Female<br/>Genotype<br/>Humans<br/>Male<br/>Middle Aged<br/>Platelet Aggregation--drug effects<br/>Platelet Aggregation Inhibitors--administration & dosage<br/>Ticlopidine--administration & dosage<br/>Young Adult